

# THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Date : January 12, 2004

Fujio Suzuki et al.

Our Docket : SHX 332

Serial No. : 10/694,921

Group Art Unit:

Filed : October 27, 2003

Examiner :

For : USE OF GLYCYRRHIZIN AND ITS DERIVATIVES AS  
RANTES INDUCERS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

## **INFORMATION DISCLOSURE STATEMENT** **UNDER 37 C.F.R. §§ 1.56, 1.97, and 1.98**

Applicants are submitting this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98 to disclose to the U.S. Patent and Trademark Office the patents, publications, applications, and/or other references listed on the enclosed, completed PTO-1449 form(s). The filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or as an admission that the listed references are prior art for this application. Applicants respectfully request that the listed references be expressly considered during prosecution of the application, and that the references be made of record therein and appear among the "references cited" on any patents issuing therefrom.

## CONTENT OF DISCLOSURE

This Information Disclosure Statement includes (1) one page of PTO-1449 forms, and (2) a legible copy of each foreign and non-patent reference, if any, listed on the form(s). However, because this application was filed on or after July 1, 2003, no copies of U.S. patents or published U.S. patent applications are included.

## TIMING OF DISCLOSURE / FEE INFORMATION

This Information Disclosure Statement is being filed either (1) within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. § 1.53(d), or (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application. Therefore, in accordance with 37 C.F.R. § 1.97(b), no fee or statement under 37 C.F.R. § 1.97(e) is required.

Please contact the undersigned with any questions or comments regarding this Information Disclosure Statement.


### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on January 12, 2004.


  
\_\_\_\_\_  
George Painter

Respectfully submitted,

KOLISCH HARTWELL, P.C.

  
\_\_\_\_\_  
Anton E. Skaugset

Registration No. 38,617  
Customer No. 23581  
520 S.W. Yamhill Street, Suite 200  
Portland, Oregon 97204  
Telephone: (503) 224-6655  
Facsimile: (503) 295-6679  
Attorney/Agent for Applicants



SHEET 1 OF 1

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		DOCKET NUMBER SHX 332	APPLICATION NUMBER 10/694,921
		APPLICANTS Fujio Suzuki et al.	
		FILING DATE October 27, 2003	GROUP ART UNIT

#### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPROP.

#### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES	NO

#### OTHER DOCUMENTS

Schrum et al., "Synthesis of the CC-Chemokines MIP-1 $\alpha$ , MIP-1 $\beta$ , and RANTES Is Associated With a Type 1 Immune Response," <i>The Journal of Immunology</i> , Vol. 157 (1996), pp. 3598-3604.
Siveke et al., "Cutting Edge: T Helper 1 and T Helper 2 Cells Respond Differentially to Chemokines," <i>The Journal of Immunology</i> , Vol. 160 (1998), pp. 550-554.
Cocchi et al., "Identification of RANTES, MIP-1 $\alpha$ , and MIP-1 $\beta$ as the Major HIV-Suppressive Factors Produced by CD8 $^{+}$ Cells, <i>Science</i> , Vol. 270 (Dec. 15, 1995), pp. 1811-1814.
Moriuchi et al., "Roles of Chemokines and Chemokine Receptors in HIV Disease: Implications for Mechanisms of Infection and Therapeutic Interventions," <i>Saibou Kougaku</i> , Vol. 19, No. 5 (2000), pp. 732-737.

EXAMINER	DATE CONSIDERED
----------	-----------------